Search results
Test Details. Methodology. Nucleic Acid Amplification Test (NAAT) includes RT-PCR or TMA. Assay Category. This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories. Reference Range (s) Not detected. Alternative Name (s) Novel Coronavirus,Wuhan,COVID19,nCOV,Coronavirus.
May 12, 2023 · Amplifying those nucleic acids enables NAATs to detect very small amounts of SARS-CoV-2 RNA in a specimen, making these tests highly sensitive for diagnosing COVID-19. In other words, NAATs can reliably detect small amounts of SARS-CoV-2 and are unlikely to return a false-negative result of SARS-CoV-2.
Deprecated SARS-CoV-2 (COVID-19) in Respiratory specimen by NAA with probe detection: 103202-8: Deprecated SARS-CoV-2 (COVID-19) RNA in Respiratory specimen by NAA with probe detection: 95941-1: Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection ...
Qualitative detection of SARS coronavirus 2 (SARS-CoV-2) in various specimens, including lower & upper respiratory, serum, stool or urine, by nucleic acid amplification with probe-based detection. Results may be based on multiple assays to determine the presence of the virus in a specimen.
Mar 18, 2024 · Updated Mar. 18, 2024. Print. Key Points. People who have symptoms of COVID-19 or who have had known exposure to someone with COVID-19 should be tested for SARS-CoV-2 infection. Screening testing may be appropriate in some specific settings. On This Page. Considerations When Testing. Testing for SARS-CoV-2 Infection.
Dec 20, 2023 · For diagnosing current SARS-CoV-2 infection, the CDC recommends using a specimen from the upper respiratory tract (e.g., nasal, nasopharyngeal). 5 Testing lower respiratory tract specimens is also an option in certain circumstances (e.g., in those receiving mechanical ventilation).
